Biocon shares rise 2% after USFDA approval for osteoporosis and bone loss drugs
Shares of Biocon Ltd rose 2% to Rs 361.25 on the BSE after its subsidiary, Biocon Biologics, received U.S. FDA approval for two denosumab biosimilars, Bosaya and Aukelso. The regulator also granted provisional interchangeability for both drugs, allowing pharmacy-level substitution, which could (...)
Site référencé: The Economic Times
The Economic Times
How Huawei plans to outperform global tech leaders with less powerful chips
18/09/2025
Roche to acquire liver drug developer 89bio for up to $3.5 billion
18/09/2025
Nightmare at Nestlé : The world's biggest food company faces a reckoning
18/09/2025
Urban Company shares rally 69% from IPO issue price on day 2 of trading. Time to cash out or double down ?
18/09/2025
Forget gold or even silver. Platinum is outperforming both with 57% rally in 2025
18/09/2025
The 'most colorful home in Queens' has a dark secret
18/09/2025
